Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Exploratory, Open-label, Phase IV, Blinded Endpoint, Multicenter and Prospective Study to Evaluate the Effect of the Addition of Esmolol on the Current Therapeutic Regimen Used for the Treatment of Hemorrhagic Stroke

NCT03743103 is registered in ClinicalTrials.gov with Cristália Produtos Químicos Farmacêuticos Ltda. as lead sponsor.

NCT NCT03743103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03743103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Exploratory, Open-label, Phase IV, Blinded Endpoint, Multicenter and Prospective Study to Evaluate the Effect of the Addition of Esmolol on the Current Therapeutic Regimen Used for the Treatment of Hemorrhagic Stroke
Lead sponsor
Cristália Produtos Químicos Farmacêuticos Ltda.
Phase
Phase 4
Overall status
Terminated
Start date
April 18, 2019
Completion date
October 31, 2021
Enrollment
20 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hemorrhagic stroke